We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34(+) (10(5) cells/mL) or light-density (10(6) cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol(10(-6) M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated congruent to 1-2 x 10(7) erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45(low)/glycophorin (GPA)(neg)/CD71(low) cells at day 7, 50 - 60% of which became CD45(neg)/GPA(+)/CD71(high) by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine(pos) and CD45(neg)/GPA(+)/CD71(medium)) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.

In Vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients

DI PIETRO, Roberta;DI GIACOMO, Viviana;DI BALDASSARRE, Angela;
2002-01-01

Abstract

We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34(+) (10(5) cells/mL) or light-density (10(6) cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol(10(-6) M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated congruent to 1-2 x 10(7) erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45(low)/glycophorin (GPA)(neg)/CD71(low) cells at day 7, 50 - 60% of which became CD45(neg)/GPA(+)/CD71(high) by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine(pos) and CD45(neg)/GPA(+)/CD71(medium)) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1079979602905024-main.pdf

accesso aperto

Tipologia: Documento in Pre-print
Dimensione 182.08 kB
Formato Adobe PDF
182.08 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/675922
Citazioni
  • ???jsp.display-item.citation.pmc??? 64
  • Scopus 120
  • ???jsp.display-item.citation.isi??? 114
social impact